{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:39:38Z","timestamp":1790620778976,"version":"4.1.0"},"reference-count":163,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic \u03b2-cells or a reduction in \u03b2-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on \u03b2-cell physiology as well as by expanding or at least maintaining \u03b2-cell mass, which may delay the progression of the disease. Long-term studies in humans are needed to elaborate on these effects.<\/jats:p>","DOI":"10.1210\/er.2007-0031","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T16:44:32Z","timestamp":1210783472000},"page":"367-379","source":"Crossref","is-referenced-by-count":91,"title":["Targeting \u03b2-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins"],"prefix":"10.1210","volume":"29","author":[{"given":"Marzieh","family":"Salehi","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267-0547"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt A.","family":"Aulinger","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267-0547"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"D'Alessio","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, University of Cincinnati, Cincinnati, Ohio 45267-0547"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2008,2,21]]},"reference":[{"key":"2020071611574467700_R1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2337\/diabetes.40.2.166","article-title":"Banting lecture 1990. \u03b2-Cells in type II diabetes mellitus.","volume":"40","author":"Porte Jr","year":"1991","journal-title":"Diabetes"},{"key":"2020071611574467700_R2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI110398","article-title":"Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and \u03b2-cell glucose sensitivity from the response to intravenous glucose.","volume":"68","author":"Bergman","year":"1981","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","article-title":"Quantification of the relationship between insulin sensitivity and \u03b2-cell function in human subjects. Evidence for a hyperbolic function.","volume":"42","author":"Kahn","year":"1993","journal-title":"Diabetes"},{"key":"2020071611574467700_R4","first-page":"4047","article-title":"Clinical review 135: the importance of \u03b2-cell failure in the development and progression of type 2 diabetes.","volume":"86","author":"Kahn","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R5","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/414788a","article-title":"Diabetes mellitus and genetically programmed defects in \u03b2-cell function.","volume":"414","author":"Bell","year":"2001","journal-title":"Nature"},{"key":"2020071611574467700_R6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1210\/jc.2004-1133","article-title":"\u03b2-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis.","volume":"90","author":"Ferrannini","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R7","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","volume":"44","journal-title":"Diabetes"},{"key":"2020071611574467700_R8","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","article-title":"Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects.","volume":"46","author":"Perley","year":"1967","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R9","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198805123181903","article-title":"Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus.","volume":"318","author":"Polonsky","year":"1988","journal-title":"N Engl J Med"},{"key":"2020071611574467700_R10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1172\/JCI105534","article-title":"Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus.","volume":"46","author":"Seltzer","year":"1967","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R11","first-page":"E572","article-title":"Elevated plasma glucose 2 h postchallenge predicts defects in \u03b2-cell function","volume":"270","author":"Byrne","year":"1996","journal-title":"Am J Physiol"},{"key":"2020071611574467700_R12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"2020071611574467700_R13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1172\/JCI111542","article-title":"Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.","volume":"74","author":"Ward","year":"1984","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s125-002-8248-z","article-title":"Reduced \u03b2-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients.","volume":"45","author":"Sakuraba","year":"2002","journal-title":"Diabetologia"},{"key":"2020071611574467700_R15","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2002-020735","article-title":"Selective \u03b2-cell loss and \u03b1-cell expansion in patients with type 2 diabetes mellitus in Korea.","volume":"88","author":"Yoon","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"\u03b2-Cell deficit and increased \u03b2-cell apoptosis in humans with type 2 diabetes.","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"2020071611574467700_R17","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/db05-1672","article-title":"\u03b2-Cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes.","volume":"55","author":"Matveyenko","year":"2006","journal-title":"Diabetes"},{"key":"2020071611574467700_R18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/diabetes.48.2.241","article-title":"Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes.","volume":"48","author":"Kahn","year":"1999","journal-title":"Diabetes"},{"key":"2020071611574467700_R19","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/diacare.29.03.06.dc05-1538","article-title":"Relationship between \u03b2-cell mass and fasting blood glucose concentration in humans.","volume":"29","author":"Ritzel","year":"2006","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2337\/diabetes.50.1.47","article-title":"Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis.","volume":"50","author":"Robertson","year":"2001","journal-title":"Diabetes"},{"key":"2020071611574467700_R21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/diacare.13.6.610","article-title":"Glucose toxicity.","volume":"13","author":"Rossetti","year":"1990","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI200215318","article-title":"Glucose-induced \u03b2 cell production of IL-1\u03b2 contributes to glucotoxicity in human pancreatic islets.","volume":"110","author":"Maedler","year":"2002","journal-title":"J Clin Invest"},{"issue":"Suppl 3","key":"2020071611574467700_R23","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"2020071611574467700_R24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI113470","article-title":"Minimal chronic hyperglycemia is a critical determinant of impaired insulin secretion after an incomplete pancreatectomy.","volume":"81","author":"Leahy","year":"1988","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00125-004-1336-4","article-title":"Decreased \u03b2-cell mass in diabetes: significance, mechanisms and therapeutic implications.","volume":"47","author":"Donath","year":"2004","journal-title":"Diabetologia"},{"key":"2020071611574467700_R26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/01.TP.0000113231.90613.0E","article-title":"Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health Workshop on \u03b2 Cell Imaging.","volume":"77","author":"Paty","year":"2004","journal-title":"Transplantation"},{"key":"2020071611574467700_R27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1172\/JCI118387","article-title":"Mechanism of impaired glucose-potentiated insulin secretion in diabetic 90% pancreatectomy rats. Study using glucagonlike peptide-1 (7-37).","volume":"97","author":"Hosokawa","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1677\/jme.0.0240297","article-title":"Islet growth and development in the adult.","volume":"24","author":"Bonner-Weir","year":"2000","journal-title":"J Mol Endocrinol"},{"key":"2020071611574467700_R29","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/endo-121-4-1447","article-title":"Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet B cells.","volume":"121","author":"Sorenson","year":"1987","journal-title":"Endocrinology"},{"key":"2020071611574467700_R30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0092-8674(00)81896-6","article-title":"Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles.","volume":"88","author":"Bruning","year":"1997","journal-title":"Cell"},{"key":"2020071611574467700_R31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1210\/endo-124-3-1571","article-title":"Compensatory adaption to partial pancreatectomy in the rat.","volume":"124","author":"Lee","year":"1989","journal-title":"Endocrinology"},{"key":"2020071611574467700_R32","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/BF00281990","article-title":"New developments in the incretin concept.","volume":"28","author":"Creutzfeldt","year":"1985","journal-title":"Diabetologia"},{"key":"2020071611574467700_R33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance.","volume":"41","author":"McIntyre","year":"1964","journal-title":"Lancet"},{"key":"2020071611574467700_R34","first-page":"85","author":"D'Alessio","year":"2002"},{"key":"2020071611574467700_R35","first-page":"439","author":"Wolfe","year":"1999"},{"key":"2020071611574467700_R36","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1172\/JCI118411","article-title":"Gastric emptying and release of incretin hormones after glucose ingestion in humans.","volume":"97","author":"Schirra","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/dmr.5610030101","article-title":"Gastrointestinal peptides and insulin secretion.","volume":"3","author":"Ebert","year":"1987","journal-title":"Diabetes Metab Rev"},{"key":"2020071611574467700_R38","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"key":"2020071611574467700_R39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/diab.44.3.249","article-title":"Dynamics of \u03b2-cell mass in the growing rat pancreas. Estimation with a simple mathematical model.","volume":"44","author":"Finegood","year":"1995","journal-title":"Diabetes"},{"key":"2020071611574467700_R40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones.","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"2020071611574467700_R41","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1210\/endo.141.3.7366","article-title":"Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors.","volume":"141","author":"Bollag","year":"2000","journal-title":"Endocrinology"},{"key":"2020071611574467700_R42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/dmr.5610080206","article-title":"Gut hormones and diabetes mellitus.","volume":"8","author":"Creutzfeldt","year":"1992","journal-title":"Diabetes Metab Rev"},{"key":"2020071611574467700_R43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1515\/BC.2004.110","article-title":"Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice.","volume":"385","author":"Irwin","year":"2004","journal-title":"Biol Chem"},{"key":"2020071611574467700_R44","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1172\/JCI119060","article-title":"Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.","volume":"98","author":"Tseng","year":"1996","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R45","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1073\/pnas.96.26.14843","article-title":"Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.","volume":"96","author":"Miyawaki","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611574467700_R46","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/edrv.20.6.0385","article-title":"The glucagon-like peptides.","volume":"20","author":"Kieffer","year":"1999","journal-title":"Endocr Rev"},{"key":"2020071611574467700_R47","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1210\/jc.2002-021873","article-title":"Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.","volume":"88","author":"Vilsboll","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R48","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"key":"2020071611574467700_R49","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2337\/diacare.26.3.791","article-title":"Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.","volume":"26","author":"Quddusi","year":"2003","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R50","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide- 1 receptor.","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"key":"2020071611574467700_R51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autneu.2003.11.001","article-title":"Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells.","volume":"110","author":"Nakagawa","year":"2004","journal-title":"Auton Neurosci"},{"key":"2020071611574467700_R52","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/en.2006-0153","article-title":"GLP-1 receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats.","volume":"148","author":"Vahl","year":"2007","journal-title":"Endocrinology"},{"key":"2020071611574467700_R53","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2337\/diab.47.1.57","article-title":"Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic \u03b2-cells by both proximal and distal regulatory steps in stimulus-secretion coupling.","volume":"47","author":"Gromada","year":"1998","journal-title":"Diabetes"},{"key":"2020071611574467700_R54","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1172\/JCI119482","article-title":"Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.","volume":"99","author":"Wang","year":"1997","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R55","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat Med"},{"key":"2020071611574467700_R56","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.2337\/diabetes.50.8.1720","article-title":"Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.","volume":"50","author":"Burcelin","year":"2001","journal-title":"Diabetes"},{"key":"2020071611574467700_R57","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2337\/diabetes.52.1.124","article-title":"Glucagon-like peptide 1 induces pancreatic \u03b2-cell proliferation via transactivation of the epidermal growth factor receptor.","volume":"52","author":"Buteau","year":"2003","journal-title":"Diabetes"},{"key":"2020071611574467700_R58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2337\/diabetes.52.2.365","article-title":"Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy.","volume":"52","author":"De Leon","year":"2003","journal-title":"Diabetes"},{"key":"2020071611574467700_R59","doi-asserted-by":"crossref","first-page":"E931","DOI":"10.1152\/ajpendo.00270.2002","article-title":"Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis","volume":"284","author":"Pamir","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071611574467700_R60","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.2337\/diabetes.47.7.1046","article-title":"Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor \u2212\/\u2212 mice.","volume":"47","author":"Pederson","year":"1998","journal-title":"Diabetes"},{"key":"2020071611574467700_R61","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1210\/jcem-41-2-260","article-title":"Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man.","volume":"41","author":"Falko","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/diab.27.3.327","article-title":"Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects.","volume":"27","author":"Ross","year":"1978","journal-title":"Diabetes"},{"key":"2020071611574467700_R63","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2362.1992.tb01464.x","article-title":"Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man.","volume":"22","author":"Eissele","year":"1992","journal-title":"Eur J Clin Invest"},{"key":"2020071611574467700_R64","doi-asserted-by":"crossref","first-page":"E939","DOI":"10.1152\/ajpendo.00197.2004","article-title":"Neural regulation of glucagon-like peptide-1 secretion in pigs","volume":"287","author":"Hansen","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071611574467700_R65","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/endo.140.4.6643","article-title":"Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.","volume":"140","author":"Rocca","year":"1999","journal-title":"Endocrinology"},{"key":"2020071611574467700_R66","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.","volume":"50","author":"Vilsboll","year":"2001","journal-title":"Diabetes"},{"key":"2020071611574467700_R67","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"key":"2020071611574467700_R68","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.2337\/diabetes.54.8.2436","article-title":"Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes.","volume":"54","author":"Gault","year":"2005","journal-title":"Diabetes"},{"key":"2020071611574467700_R69","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity.","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"key":"2020071611574467700_R70","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1210\/me.2005-0187","article-title":"Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion.","volume":"20","author":"Tsukiyama","year":"2006","journal-title":"Mol Endocrinol"},{"key":"2020071611574467700_R71","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.bone.2007.01.007","article-title":"Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass.","volume":"40","author":"Xie","year":"2007","journal-title":"Bone"},{"key":"2020071611574467700_R72","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":"Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"key":"2020071611574467700_R73","first-page":"E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am J Physiol"},{"key":"2020071611574467700_R74","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.","volume":"38","author":"Wettergren","year":"1993","journal-title":"Dig Dis Sci"},{"key":"2020071611574467700_R75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R76","doi-asserted-by":"crossref","first-page":"E701","DOI":"10.1152\/ajpendo.00024.2003","article-title":"Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect","volume":"285","author":"Prigeon","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071611574467700_R77","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1172\/JCI117225","article-title":"Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.","volume":"93","author":"D'Alessio","year":"1994","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R78","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1210\/jcem.87.8.8743","article-title":"Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.","volume":"87","author":"Egan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R79","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/edrv-9-1-122","article-title":"Immunoreactive gastric inhibitory polypeptide.","volume":"9","author":"Krarup","year":"1988","journal-title":"Endocr Rev"},{"key":"2020071611574467700_R80","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI115012","article-title":"Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.","volume":"87","author":"Orskov","year":"1991","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00838486","article-title":"Response of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide to glucose ingestion in non-insulin dependent diabetes mellitus. Effect of sulfonylurea therapy.","volume":"32","author":"Fukase","year":"1995","journal-title":"Acta Diabetol"},{"key":"2020071611574467700_R82","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/eje.0.1350425","article-title":"Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)\u2013evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.","volume":"135","author":"Vaag","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"2020071611574467700_R83","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jcem.86.8.7750","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R84","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"2020071611574467700_R85","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/eje.1.02221","article-title":"Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.","volume":"155","author":"Ryskjaer","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"2020071611574467700_R86","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1210\/jc.2004-0334","article-title":"Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes.","volume":"89","author":"O'Donovan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0167-0115(94)90136-8","article-title":"The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.","volume":"51","author":"Elahi","year":"1994","journal-title":"Regul Pept"},{"key":"2020071611574467700_R88","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"2020071611574467700_R89","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0026-0495(87)90153-3","article-title":"Effect of porcine gastric inhibitory polypeptide on \u03b2-cell function in type I and type II diabetes mellitus.","volume":"36","author":"Krarup","year":"1987","journal-title":"Metabolism"},{"key":"2020071611574467700_R90","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1007\/s00125-005-1863-7","article-title":"Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.","volume":"48","author":"Meier","year":"2005","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"2020071611574467700_R91","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.2337\/diabetes.53.suppl_3.S220","article-title":"Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"key":"2020071611574467700_R92","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2337\/diab.45.11.1524","article-title":"Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.","volume":"45","author":"Rachman","year":"1996","journal-title":"Diabetes"},{"key":"2020071611574467700_R93","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s001250050664","article-title":"Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.","volume":"40","author":"Rachman","year":"1997","journal-title":"Diabetologia"},{"key":"2020071611574467700_R94","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-stimulated insulin secretion: effects on \u03b2-cell sensitivity in type 2 and nondiabetic subjects.","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"key":"2020071611574467700_R95","first-page":"473","article-title":"Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.","volume":"82","author":"Ahren","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R96","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and \u03b2-cell function in type 2 diabetes: a parallel-group study.","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"2020071611574467700_R97","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nature02520","article-title":"Adult pancreatic \u03b2-cells are formed by self-duplication rather than stem-cell differentiation.","volume":"429","author":"Dor","year":"2004","journal-title":"Nature"},{"key":"2020071611574467700_R98","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/ncpendmet0187","article-title":"\u03b2-Cell proliferation is the major source of new pancreatic \u03b2 cells.","volume":"2","author":"Dor","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2020071611574467700_R99","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.devcel.2007.04.011","article-title":"Growth and regeneration of adult \u03b2 cells does not involve specialized progenitors.","volume":"12","author":"Teta","year":"2007","journal-title":"Dev Cell"},{"key":"2020071611574467700_R100","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.","volume":"84","author":"Drucker","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611574467700_R101","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.2337\/diabetes.49.7.1156","article-title":"Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element.","volume":"49","author":"Skoglund","year":"2000","journal-title":"Diabetes"},{"key":"2020071611574467700_R102","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1210\/endo.142.5.8128","article-title":"Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic \u03b2-cells by a cyclic adenosine monophosphate\/protein kinase A-dependent mechanism.","volume":"142","author":"Wang","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611574467700_R103","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1113\/jphysiol.2006.119644","article-title":"Cell physiology of cAMP sensor Epac.","volume":"577","author":"Holz","year":"2006","journal-title":"J Physiol"},{"key":"2020071611574467700_R104","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2337\/diabetes.50.10.2237","article-title":"Protein kinase C\u03b6 activation mediates glucagon-like peptide-1-induced pancreatic \u03b2-cell proliferation.","volume":"50","author":"Buteau","year":"2001","journal-title":"Diabetes"},{"key":"2020071611574467700_R105","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s00125-002-0828-3","article-title":"Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db\/db mice.","volume":"45","author":"Wang","year":"2002","journal-title":"Diabetologia"},{"key":"2020071611574467700_R106","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s00125-005-1692-8","article-title":"Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells.","volume":"48","author":"Wang","year":"2005","journal-title":"Diabetologia"},{"key":"2020071611574467700_R107","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbrc.2005.03.013","article-title":"The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits \u03b2-cell apoptosis in vitro.","volume":"330","author":"Bregenholt","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071611574467700_R108","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2337\/diabetes.51.3.691","article-title":"NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1.","volume":"51","author":"Lawrence","year":"2002","journal-title":"Diabetes"},{"key":"2020071611574467700_R109","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature05097","article-title":"Calcineurin\/NFAT signalling regulates pancreatic \u03b2-cell growth and function.","volume":"443","author":"Heit","year":"2006","journal-title":"Nature"},{"key":"2020071611574467700_R110","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/diabetes.50.4.785","article-title":"Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells.","volume":"50","author":"Hui","year":"2001","journal-title":"Diabetes"},{"key":"2020071611574467700_R111","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1677\/jme.0.0290347","article-title":"Cultured pancreatic ductal cells undergo cell cycle re-distribution and \u03b2-cell-like differentiation in response to glucagon-like peptide-1.","volume":"29","author":"Bulotta","year":"2002","journal-title":"J Mol Endocrinol"},{"key":"2020071611574467700_R112","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1210\/endo.143.8.8973","article-title":"Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin- producing cells.","volume":"143","author":"Abraham","year":"2002","journal-title":"Endocrinology"},{"key":"2020071611574467700_R113","doi-asserted-by":"crossref","first-page":"48146","DOI":"10.1074\/jbc.M209165200","article-title":"cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic \u03b2-cells.","volume":"277","author":"Gomez","year":"2002","journal-title":"J Biol Chem"},{"key":"2020071611574467700_R114","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.49.5.741","article-title":"Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.","volume":"49","author":"Stoffers","year":"2000","journal-title":"Diabetes"},{"key":"2020071611574467700_R115","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.2337\/diabetes.48.12.2270","article-title":"Exendin-4 stimulates both \u03b2-cell replication and neogenesis, resulting in increased \u03b2-cell mass and improved glucose tolerance in diabetic rats.","volume":"48","author":"Xu","year":"1999","journal-title":"Diabetes"},{"key":"2020071611574467700_R116","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1210\/en.2002-220897","article-title":"Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5\u2032-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.","volume":"144","author":"Hui","year":"2003","journal-title":"Endocrinology"},{"key":"2020071611574467700_R117","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2337\/diabetes.51.4.943","article-title":"Long-term treatment with the dipeptidyl peptidase IV inhibitor P32\/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and \u03b2-cell glucose responsiveness in VDF (fa\/fa) Zucker rats.","volume":"51","author":"Pospisilik","year":"2002","journal-title":"Diabetes"},{"key":"2020071611574467700_R118","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas.","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol Ther"},{"key":"2020071611574467700_R119","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db05-0825","article-title":"Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic \u03b2-cell mass.","volume":"55","author":"Buteau","year":"2006","journal-title":"Diabetes"},{"key":"2020071611574467700_R120","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.","volume":"143","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"2020071611574467700_R121","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/endo.141.12.7806","article-title":"Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.","volume":"141","author":"Perfetti","year":"2000","journal-title":"Endocrinology"},{"key":"2020071611574467700_R122","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.gt.3302944","article-title":"In vivo expression of GLP-1\/IgG-Fc fusion protein enhances \u03b2-cell mass and protects against streptozotocin-induced diabetes.","volume":"14","author":"Soltani","year":"2007","journal-title":"Gene Ther"},{"key":"2020071611574467700_R123","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2337\/diabetes.50.7.1562","article-title":"Glucagon-like peptide-1 and exendin-4 stimulate \u03b2-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.","volume":"50","author":"Tourrel","year":"2001","journal-title":"Diabetes"},{"key":"2020071611574467700_R124","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00125-006-0251-2","article-title":"Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.","volume":"49","author":"Sharma","year":"2006","journal-title":"Diabetologia"},{"key":"2020071611574467700_R125","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.biocel.2005.08.005","article-title":"In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice.","volume":"38","author":"Suen","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"2020071611574467700_R126","doi-asserted-by":"crossref","first-page":"13468","DOI":"10.1073\/pnas.0600655103","article-title":"Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).","volume":"103","author":"Wideman","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611574467700_R127","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ncpendmet0647","article-title":"The replication of \u03b2 cells in normal physiology, in disease and for therapy.","volume":"3","author":"Butler","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"2020071611574467700_R128","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/01.tp.0000251379.46596.2d","article-title":"Effect of exenatide on \u03b2 cell function after islet transplantation in type 1 diabetes.","volume":"83","author":"Ghofaili","year":"2007","journal-title":"Transplantation"},{"key":"2020071611574467700_R129","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0006-291X(84)90281-X","article-title":"Functional GIP receptors in a hamster pancreatic \u03b2 cell line, In 111: specific binding and biological effects.","volume":"123","author":"Amiranoff","year":"1984","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071611574467700_R130","doi-asserted-by":"crossref","first-page":"46046","DOI":"10.1074\/jbc.M108378200","article-title":"Critical role of cAMP-GEFII\u2013Rim2 complex in incretin-potentiated insulin secretion.","volume":"276","author":"Kashima","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071611574467700_R131","first-page":"1559","article-title":"Glucose-dependent insulinotropic polypeptide is a growth factor for \u03b2 (INS-1) cells by pleiotropic signaling.","volume":"15","author":"Trumper","year":"2001","journal-title":"Mol Endocrinol"},{"key":"2020071611574467700_R132","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1210\/en.2002-0068","article-title":"Glucose-dependent insulinotropic polypeptide promotes \u03b2-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.","volume":"144","author":"Ehses","year":"2003","journal-title":"Endocrinology"},{"key":"2020071611574467700_R133","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R134","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/joe.0.1740233","article-title":"Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in \u03b2 (INS-1)-cells.","volume":"174","author":"Trumper","year":"2002","journal-title":"J Endocrinol"},{"key":"2020071611574467700_R135","doi-asserted-by":"crossref","first-page":"6825","DOI":"10.1073\/pnas.0631828100","article-title":"Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance.","volume":"100","author":"Conarello","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611574467700_R136","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.2337\/diacare.27.12.2874","article-title":"Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.","volume":"27","author":"Ahren","year":"2004","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R137","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA"},{"key":"2020071611574467700_R138","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.2337\/diacare.27.8.1915","article-title":"The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.","volume":"27","author":"Harder","year":"2004","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R139","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.","volume":"62","author":"Kolterman","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"2020071611574467700_R140","doi-asserted-by":"crossref","first-page":"E155","DOI":"10.1152\/ajpendo.2001.281.1.E155","article-title":"Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers","volume":"281","author":"Edwards","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071611574467700_R141","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jcem.87.3.8337","article-title":"The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.","volume":"87","author":"Egan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R142","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.2337\/diabetes.53.9.2397","article-title":"Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.","volume":"53","author":"Degn","year":"2004","journal-title":"Diabetes"},{"key":"2020071611574467700_R143","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R144","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1210\/jc.2005-1093","article-title":"Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.","volume":"90","author":"Fehse","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611574467700_R145","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R146","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R147","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-146-7-200704030-00003","article-title":"The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.","volume":"146","author":"Zinman","year":"2007","journal-title":"Ann Intern Med"},{"key":"2020071611574467700_R148","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","article-title":"Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.","volume":"29","author":"Buse","year":"2007","journal-title":"Clin Ther"},{"key":"2020071611574467700_R149","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00125-001-0719-z","article-title":"The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.","volume":"45","author":"Agerso","year":"2002","journal-title":"Diabetologia"},{"key":"2020071611574467700_R150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.2337\/diabetes.51.2.424","article-title":"Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.","volume":"51","author":"Juhl","year":"2002","journal-title":"Diabetes"},{"key":"2020071611574467700_R151","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2337\/diabetes.52.7.1786","article-title":"The GLP-1 derivative NN2211 restores \u03b2-cell sensitivity to glucose in type 2 diabetic patients after a single dose.","volume":"52","author":"Chang","year":"2003","journal-title":"Diabetes"},{"key":"2020071611574467700_R152","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/diacare.27.6.1335","article-title":"Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.","volume":"27","author":"Madsbad","year":"2004","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R153","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R154","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R155","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.2337\/dc06-0706","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.","volume":"29","author":"Charbonnel","year":"2006","journal-title":"Diabetes Care"},{"key":"2020071611574467700_R156","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.clinthera.2006.10.007","article-title":"Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.","volume":"28","author":"Rosenstock","year":"2006","journal-title":"Clin Ther"},{"key":"2020071611574467700_R157","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"2020071611574467700_R158","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1007\/s00125-007-0737-6","article-title":"Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes.","volume":"50","author":"Zhang","year":"2007","journal-title":"Diabetologia"},{"key":"2020071611574467700_R159","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.surg.2007.03.001","article-title":"How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and \u03b2-cell function in Goto-kakizaki rats through an enhanced proglucagon gene expression and L-cell number.","volume":"142","author":"Patriti","year":"2007","journal-title":"Surgery"},{"key":"2020071611574467700_R160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1074\/jbc.M209423200","article-title":"Glucagon-like peptide-1 receptor signaling modulates \u03b2 cell apoptosis.","volume":"278","author":"Li","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071611574467700_R161","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1210\/en.2004-1349","article-title":"Exenatide (exendin-4) improves insulin sensitivity and \u03b2-cell mass in insulin-resistant obese fa\/fa Zucker rats independent of glycemia and body weight.","volume":"146","author":"Gedulin","year":"2005","journal-title":"Endocrinology"},{"key":"2020071611574467700_R162","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic \u03b2-cell mass and function in a rodent model of type 2 diabetes.","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"2020071611574467700_R163","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1530\/eje.0.1460717","article-title":"Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.","volume":"146","author":"Reimer","year":"2002","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/29\/3\/367\/8862990\/edrv0367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/29\/3\/367\/8862990\/edrv0367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T18:12:26Z","timestamp":1594923146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/29\/3\/367\/2355013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,21]]},"references-count":163,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2007-0031","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,21]]}}}